This article appears in the following Journal of Antimicrobial Chemotherapy issue: Daptomycin development and clinical experience [View the issue table of contents]
Preface |
Preface
The emergence and spread of antibiotic-resistant bacteria continue to fuel the need for new antimicrobial agents. When new agents are developed and introduced into clinical use, clinicians and infection specialists must decide for which indications they should either be used or held in reserve, what are the optimal doses and duration of administration and what steps can be taken to minimize the likelihood of resistance emerging.
Daptomycin is one of the newest antibacterial agents to be licensed. It belongs to a novel class of antibiotics, the cyclic lipopeptides, and shows potent bactericidal activity against Gram-positive bacteria, including those resistant to first-line agents, such as methicillin-resistant Staphylococcus aureus. The series of papers in this Supplement brings together a wealth of data on the biology of daptomycin (including its in vitro activity and mode of action) and its efficacy in a number of clinical settings including skin and soft tissue infections, bacteraemia and endocarditis. The latter data are derived from both randomized clinical trials and analysis of post-licensing registry data. We hope that this Supplement will provide a valuable and useful source of information on this important new addition to the antibiotic armamentarium, as well as highlighting areas where further research is required.
 |
Transparency declarations |
|---|
 Top Transparency declarations |
|---|
K. G. and A. P. J. have received honoraria or funding from various pharmaceutical companies including Novartis for speaking, conference attendance, research work or consultancy.
CiteULike 
Connotea 
Del.icio.us What's this?
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||